This ITC found comparable efficacy (measured using time to beginning of symptom relief) and safety (measured using treatment-related TEAEs) between sebetralstat, an investigational, oral plasma kallikrein inhibitor, and intravenous rhC1INH for the on-demand treatment of HAE attacks. This evidence concerns the gene KLK4 and hereditary angioedema.